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Abstract
Introduction: Combined genotyping/whole genome sequencing and epidemiological data suggest that in endemic
settings only a minority of Clostridium difficile infection, CDI, is acquired from other cases. Asymptomatic patients are a
potential source for many unexplained cases.
Methods: We prospectively screened a cohort of medical inpatients in a UK teaching hospital for asymptomatic C. difficile
carriage using stool culture. Electronic and questionnaire data were used to determine risk factors for asymptomatic
carriage by logistic regression. Carriage isolates were compared with all hospital/community CDI cases from the same
geographic region, from 12 months before the study to 3 months after, using whole genome sequencing and hospital
admission data, assessing particularly for evidence of onward transmission from asymptomatic cases.
Results: Of 227 participants recruited, 132 provided $1 stool samples for testing. 18 participants were culture-positive for C.
difficile, 14/132(11%) on their first sample. Independent risk factors for asymptomatic carriage were patient reported loose/
frequent stool (but not meeting CDI criteria of $3 unformed stools in 24 hours), previous overnight hospital stay within 6
months, and steroid/immunosuppressant medication in the last 6 months (all p#0.02). Surprisingly antibiotic exposure in
the last 6 months was independently associated with decreased risk of carriage (p = 0.005). The same risk factors were
identified excluding participants reporting frequent/loose stool. 13/18(72%) asymptomatically colonised patients carried
toxigenic strains from common disease-causing lineages found in cases. Several plausible transmission events to
asymptomatic carriers were identified, but in this relatively small study no clear evidence of onward transmission from an
asymptomatic case was seen.
Conclusions: Transmission events from any one asymptomatic carrier are likely to be relatively rare, but as asymptomatic
carriage is common, it may still be an important source of CDI, which could be quantified in larger studies. Risk factors
established for asymptomatic carriage may help identify patients for inclusion in such studies.
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Introduction
Traditionally most Clostridium difficile infection (CDI) cases have
been thought to result from healthcare-based exposure to other
cases [1] and this forms the basis for many prevention measures
[2]. However, combined genotyping and hospital admission data
from two European cohorts suggest that, in these endemic settings
with appropriate infection control, contact with symptomatic cases
only accounts for the minority of disease [3,4]. Applying the
greater discriminatory power of bacterial whole genome sequenc-
ing in one of these cohorts demonstrates the majority of cases over
the 3 year study period are sufficiently genetically diverse that they
cannot be related by direct or indirect transmission irrespective of
the route of transmission [5].
Data from previous studies suggest C. difficile is typically
acquired shortly before onset of disease [6], with long term
carriage protective against CDI [7,8]. Therefore, although C.
difficile is widely found in the environment [9], recent exposure to
asymptomatic individuals, particularly in a healthcare setting,
represents a compelling potential source for many currently
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unexplained CDI cases and a potential area for intervention.
Between 4% and 15% of healthy adults may be asymptomatically
colonised [10,11]. In hospitalised adults, asymptomatic carriage
rates reported in a large Canadian study were 184/4143 (4.4%) at
admission with a further 123 (3.0%) becoming asymptomatically
colonized during their hospital stay. However the wards included
were selected to be a mix of previously high and low CDI
incidence wards, and therefore, despite the considerable size of the
study, generalising the findings is difficult [6]. Five earlier studies,
with a total of 1755 patients across a range of specialties, report
asymptomatic carriage rates at admission of 6–11%, and
acquisition rates of 4–21%, with more than 63% of these patients
remaining asymptomatic [12]. Colonisation in young children is
common, with rates ,35% in the first year of life falling to ,15%
by 1–8 years [13]. High colonisation rates are also described in
long-term care facilities, 51% in the context of an outbreak [14],
and 4–20% in endemic settings [15,16].
Compared with non-colonised patients, asymptomatic patients
have higher rates of skin and environmental contamination (but
less than that associated with symptomatic cases) [14,17,18], and
C. difficile can be recovered from investigators’ hands after contact
with colonized individuals [14]. Estimates of the extent of onward
transmission within hospitals attributable to asymptomatic carriers
vary considerably [19,20]. In one study, nosocomial acquisition of
a new C. difficile strain was preceded by initial introduction of the
strain on to a ward by an asymptomatic carrier in 16/19 (84%)
instances [19]. In another examining possible sources for recently
diagnosed cases, 5/12 symptomatic contacts had a strain matching
the new case compared to 1/19 asymptomatic contacts [20].
However these findings are based on relatively old studies and
genotyping methods. Therefore, while onward transmission from
asymptomatically colonised patients is clearly possible, its current
relative importance as a source of CDI is unclear. We therefore
prospectively screened a cohort of medical inpatients for
asymptomatic carriage of C. difficile. Carriage isolates were then
compared to all subsequent CDI cases in the same geographic
region over the following 3 months for evidence of onward
transmission from asymptomatic cases.
Methods
Setting and Participants
This study was performed at the Oxford University Hospitals
NHS Trust, OUH. The OUH consists of 1600 beds across 4
hospital sites in the English county of Oxfordshire (population
,600000). The hospitals provide all acute care to the population,
.90% of all hospital services, and all diagnostic testing for C.
difficile for hospital and community samples from the county.
All patients aged over 18 years admitted to a study ward were
eligible for inclusion. The study was conducted on acute general
medicine and geratology wards, as these specialities had the
greatest historic CDI incidence. The choice of high prevalence
wards was intended to provide the maximum number of CDI
cases on the same ward as asymptomatic carriers, in order to
investigate the potential for carrier to case transmissions. Patients
diagnosed with CDI in the last 28 days, or with a current clinical
suspicion of CDI ($3 unformed stools in a 24 hour period) were
excluded from this specific study (but samples/sequences from
these cases were available for comparison with study participants,
see below).
Recruitment was rotated around 8 study wards on a weekly to
fortnightly basis (between 02 February 2012 and 10 June 2012) to
reduce the nursing burden of sending stool samples from patients.
Following informed consent (or the advice of an appropriate
consultee in the case of patients without capacity) patients were
recruited within 24 hours of ward admission where possible
(however, no upper limit was set for the time between admission
and enrolment).
Samples
Patients were asked provide a sample of their first stool after
enrolment, and then a sample at approximately 3 day intervals
until discharge, and where possible a sample shortly prior to
discharge.
Samples were cultured in weekly batches following the method
of [21], which is very similar to that used in largest study of
asymptomatic carriage to date [6]. Samples with colonies
exhibiting a characteristic appearance, odour, and fluorescence
consistent with C. difficile underwent whole genome sequencing as
described in [5]. Briefly, indexed pools of 96 samples were
sequenced using the Illumina HiSeq 2000 platform (Illumina Inc,
San Diego, CA) generating 100 base pair paired-end reads. Reads
were mapped with Stampy [22] to the C. difficile reference genome
630 (Genbank: AM180355.1) [23]. Samples were compared using
single nucleotide variants (SNVs) identified with Samtools [24]
after quality filtering. For each sequence the presence or absence
of toxin genes and an in silico multilocus sequence type, MLST,
was determined from de novo assemblies constructed with Velvet
[25] using BLAST.
CDI Cases for Comparison
All Oxfordshire hospital and community clinical CDI cases
from April 2011 to August 2012 inclusive were considered for
comparison. During this time all hospital inpatients with $3
unformed stools in 24 hours underwent C. difficile testing. Between
April 2011 and March 2012 samples sent to the OUH
microbiology laboratory underwent toxin EIA-testing, and EIA-
positive samples were cultured. Between April 2012 and August
2012 samples were screened with a GDH test, with a follow up
confirmatory EIA test in GDH-positive samples. All GDH-positive
samples were cultured, regardless of the subsequent EIA result.
This enabled potential C. difficile ‘excretors’ carrying C. difficile, but
not currently producing toxin, to be included. Between April 2011
and August 2012 a total of 505 symptomatic C. difficile culture-
positive samples were identified, 481 (95%) of which were
successfully whole genome sequenced and available for compar-
ison. A further 137 sequences were available from a C. difficile
diagnostic study, conducted between April 2011 and September
2011, that were culture-positive, but EIA-negative [26].
Epidemiological Data
Consent was obtained for use of hospital electronic data,
including participant demographics (age, sex, postcode district
(first 3–4 characters of the postcode)), hospital admission,
discharge and ward movement data within the OUH, and
previous and future routine C. difficile testing). Additional data
on potential risks factors for C. difficile carriage were collected from
patients using a questionnaire and hospital records (see Table 1
and Table 2).
Analysis
Data obtained were used to estimate the point prevalence of
asymptomatic carriage of C. difficile. Complete assessment of
prevalence at admission and discharge, and therefore the
incidence of acquisition, was not possible given the time delay
between many participants’ recruitment and first bowel motion,
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and similarly relatively few participants providing more than one
sample (see results and discussion).
Logistic regression was used to assess associations between the
presence of C. difficile carriage in each participant’s first stool
sample and risk factors for asymptomatic carriage. Univariate and
multivariate models were fitted on cases with complete question-
naire data (n = 110/112 with any questionnaire data), with
independent risk factors identified using backwards selection with
the Akaike information criterion starting from a model including
all variables with univariate p,0.20 [27], and then the final model
re-fitted on all participants with complete data for the final
variables included (n = 111). Because of the small size of the study
we consider p,0.15 as marginal evidence of an effect and p,0.05
as significant evidence of an effect.
Whole genome sequences obtained from asymptomatic carriers
were compared to CDI cases’ sequences obtained from 1 year
prior to the study, during the study and for 3 months afterwards.
Ward movements of cases and carriers sharing closely related C.
difficile genomes were analysed for evidence of possible transmis-
sion events.
Ethics
This study was approved by the Oxford C Research Ethics
Committee (11/SC/0197). Samples from 20 asymptomatic study
ward inpatients collected as part of routine infection control
surveillance are also included in the analysis (no questionnaire
data). Use of routinely collected samples and data, including from
symptomatic patients, for the purposes of transmission analyses
was approved by the Berkshire Research Ethics Committee (10/
H0505/83) and National Information Governance Board (8–
05(e)/2010) without requiring individual patient consent.
Data Sharing
The sequences reported in this paper have been deposited in the
European Nucleotide Archive Sequence Read Archive under
study accession number ,,,Details to be provided once
accepted for publication... and are available at ,,,Details
to be provided once accepted for publication....
Table 1. Comparison of characteristics between participants returning and not returning at least one stool sample in 199
participants with questionnaire data.
Risk factor
Frequency in those not
returning samples
Frequency in those
returning samples p value
Current diarrhoea, but not meeting CDI criteria 8/86 (9%) 22/111 (20%) 0.05
Nursing home, residential home, or institutional resident 8/87 (9%) 6/112 (5%) 0.40
Inflammatory bowel disease 0/86 (0%) 1/112 (1%) 1.00
Chronic kidney disease 17/86 (20%) 24/112 (21%) 0.86
Non-haematological malignancy 4/86 (5%) 17/112 (15%) 0.02
Haematological malignancy 2/86 (2%) 5/112 (4%) 0.70
Gastrointestinal surgery in current admission 1/86 (1%) 5/112 (4%) 0.24
Nasogastric tube in place 1/86 (1%) 3/112 (3%) 0.63
Overnight hospital stay in last 6 months 41/84 (49%) 43/111 (39%) 0.19
Outpatient hospital attendance in last 6 months 24/84 (29%) 33/111 (30%) 0.88
GP visits in last 6 months, n 87 112 0.30
0 4 (5%) 9 (8%)
1–2 31 (36%) 36 (32%)
3–9 28 (32%) 46 (41%)
10+ 24 (28%) 21 (19%)
Visitor to hospital, nursing home, resident home 5/87 (6%) 3/111 (3%) 0.30
Work in healthcare 2/87 (2%) 3/111 (3%) 1.00
Healthcare worker in household 3/87 (3%) 9/111 (8%) 0.23
Previous C. difficile infection 0/87 (0%) 5/111 (5%) 0.07
Previous contact with a C. difficile infection case 3/87 (3%) 2/111 (2%) 0.66
Antibiotics in last 6 months 65/87 (75%) 90/112 (80%) 0.39
Steroids/Immunosuppressant in last 6 months 25/87 (29%) 28/112 (25%) 0.63
Gastric acid suppressant in last 6 months 25/87 (29%) 54/112 (48%) 0.006
Household pet 25/86 (29%) 27/111 (24%) 0.52
Physical contact with children $1 per month 49/86 (57%) 54/110 (49%) 0.31
Vegetarian diet 5/75 (6%) 7/111 (6%) 1.00
Foreign travel in last 6 months 3/87 (3%) 4/112 (4%) 1.00
Current smoker 10/87 (11%) 11/112 (10%) 0.82
Exact p values shown. Not all participants could answer all study questionnaire questions, as indicated in the dominator given in each line.
doi:10.1371/journal.pone.0078445.t001
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Results
Participants and Samples
Two hundred and twenty-seven participants were recruited of
243 inpatients approached (13 declined to participate and a
further 3 were ineligible due to a diagnosis of CDI in the last 28
days, Figure 1). A total of 296 stool samples were obtained from
132 participants (58% of recruited participants), 71 with a single
sample and 61 with more than one sample, median (IQR) [range]
samples per person 1 (1–2) [1–11]. Participants returning stool
samples were similar to those not returning samples in age (median
83 versus 83 years, p = 0.96), and putative risk factors for carriage,
with the exceptions that they were more likely to have current
diarrhoea not meeting CDI criteria (i.e. patient reported loose/
frequent stool, but ,3 stool samples in 24 hours taking the shape
of their container) (p = 0.05), have a non-haematological malig-
nancy (p= 0.02), and have taken gastric acid suppressant
medication in the last 6 months (p = 0.006; side effects of proton
pump inhibitors and H2-receptor antagonists include diarrhoea,
and therefore may have increased the rate of sample return in this
group) (Table 1). A total of 28 samples from 18 participants tested
positive for C. difficile (14% of those tested). 14 participants (11%)
tested positive on their first sample, with a further 4 participants
(3%) testing positive after 1, 2, 2, and 3 initially negative samples
(Figure 2). Five of the 14 participants positive on their first sample
provided subsequent samples; Participant 1 had the only apparent
loss of carriage with a positive sample followed by a negative
sample, in contrast the 4 other participants were persistently
positive on multiple testing (Figure 2). The median (IQR) [range]
time from study ward admission to enrolment was 2 (1–5) [0–44]
days; patients were admitted via a separate admissions unit, such
that an additional median (IQR) [range] 1 (0–2) [0–56] days
elapsed in hospital before admission to a study ward.
Relationship between Carriage and Previous/Subsequent
Disease
Participants were linked with hospital admission and microbi-
ology data to identify those previously or subsequently testing
positive for C. difficile as a result of clinical testing in symptomatic
patients (Figure 2). Four such participants were identified.
Participants 4, 13 and 7 had a routine microbiology laboratory
diagnosis of CDI 1, 8 and 35 days respectively after a positive
carriage test in the study. In all 3 cases no SNVs were found
between the asymptomatic study sample and the subsequent
symptomatic positive sample. Participant 7 also had a positive
routine laboratory CDI sample from 178 days prior to enrolment
which was also genetically indistinguishable to the participant’s
later samples, suggesting the single negative sample obtained from
this participant may have been falsely negative, or that this strain
was archived undetectably within the participant’s intestinal flora
and selected for by antibiotics received in hospital. In contrast,
participant 3 tested positive 86 days following a positive
asymptomatic study sample, but with a different infecting C.
difficile lineage, 11892 SNVs different from the carriage isolate.
Participants 3 and 4 reported loose or more frequent stool at the
time of enrolment, but less than the $3 unformed stools in 24
hours required to meet criteria for routine C. difficile testing.
Participants 7 and 13 had no diarrhoeal symptoms at enrolment.
Table 2. Univariate risk factors for asymptomatic carriage of C. difficile.
Risk factor
C. difficile carriers
(% total)
Non-carriers
(% total)
Odds ratio,
carriers:non-carriers 95% CI p value
Current diarrhoea, but not meeting CDI criteria 5 (50%) 17 (17%) 4.94 (1.29, 19.0) 0.02
Nursing or residential home resident 2 (20%) 4 (4%) 6.13 (0.97, 38.7) 0.08
Chronic kidney disease 2 (20%) 22 (22%) 1.10 (0.21, 5.56) 0.90
Non-haematological malignancy 3 (30%) 14 (14%) 2.69 (0.62, 11.66) 0.21
Overnight hospital stay in last 6 months 6 (60%) 37 (36%) 2.59 (0.68, 9,79) 0.15
Time in hospital during current admission prior
to enrolment, odds ratio per day*
1.00 (0.95, 1.05) 0.99
Outpatient hospital attendance in last 6 months 2 (20%) 31 (31%) 0.56 (0.11, 2.81) 0.47
GP visits in last 6 months
0 2 (20%) 7 (7%) 1.77 (0.28, 11.1) 0.23
1–2 5 (50%) 31 (30%) 1
3–9 2 (20%) 44 (43%) 0.28 (0.05, 1.55)
10+ 1 (10%) 20 (20%) 0.41 (0.03, 2.85)
Healthcare worker in household 1 (10%) 8 (8%) 1.29 (0.14, 11.52) 0.82
Antibiotics in last 6 months 6 (60%) 84 (82%) 0.32 (0.08, 1.25) 0.12
Steroids/Immunosuppressant in last 6 months 5 (50%) 23 (23%) 3.43 (0.91, 12.9) 0.07
Gastric acid suppressant in last 6 months 7 (70%) 47 (46%) 2.73 (0.67, 11.2) 0.14
Household pet 3 (33%) 24 (24%) 1.62 (0.38, 7.00) 0.52
Physical contact with children $1 per month 3 (33%) 51 (51%) 0.49 (0.11, 2.07) 0.32
Current smoker 1 (10%) 10 (10%) 1.02 (0.11, 8.92) 0.98
There were no C. difficile carriers with the following risk factors: inflammatory bowel disease (present in 1/112 (1%) participants), haematological malignancy (5/112
(4%)), gastrointestinal surgery (5/112 (4%) with surgery in current admission, 12/112 (11%) with past surgery), current nasogastric tube placement (3/112 (3%)), previous
CDI (5/112 (4%)), contact with a CDI case (2/112 (2%)), vegetarian diet (7/112 (6%)), and overseas travel (4/112 (4%)). *Given the study design, most participants spent
relatively short amounts of time in hospital prior to enrolment, median (IQR) 2 (1–6) days.
doi:10.1371/journal.pone.0078445.t002
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Figure 1. Asymptomatic study participants and samples.
doi:10.1371/journal.pone.0078445.g001
Figure 2. Temporal pattern of samples in participants with $1 positive sample. Asymptomatic positive and negative relate to samples
obtained during the carriage study. Matching of study participants with the hospital admission and microbiology data allowed 4 participants with a
subsequent symptomatic CDI positive samples to be identified, denoted symptomatic positive. 118 participants had consistently negative samples
and are not plotted.
doi:10.1371/journal.pone.0078445.g002
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Risk Factors for Carriage
Questionnaire data obtained at participant enrolment were used
to assess risk factors for C. difficile carriage in participants’ first stool
sample. A total of 112 (85%) of the 132 participants with $1 stool
samples were able to complete the study questionnaire. Ten
participants initially tested positive, a 9% point prevalence for
asymptomatic C. difficile carriage in the population tested.
Univariate odds ratios for the risk factors assessed are presented
in Table 2. The risk factor for carriage with the strongest
statistical evidence was current diarrhoea not meeting diagnostic
criteria for CDI. Patients with $3 unformed stools in a 24 hour
period, i.e. meeting OUH criteria for CDI testing, were excluded
from the study. However, 22 participants reported loose or more
frequent stool than usual, but did not meet the local criteria for
CDI testing. It is therefore possible that the five of these 22
patients testing positive for C. difficile actually should have had a
diagnosis of mild CDI (none died within the 30 days following
their sample despite not receiving CDI treatment). Non-significant
univariate trends towards increased risk of C. difficile carriage
(p,0.15) were seen with nursing or residential home residence, an
overnight stay in hospital in the last six months, steroids or another
immunosuppressant in the last six months, and gastric acid
suppressant medication in the last six months. Intriguingly any
antibiotic exposure in the last six months had a trend towards
lower risk of C. difficile carriage.
Independent risk factors in a multivariate model are shown in
Table 3 and include current diarrhoea, but not meeting CDI
criteria, overnight hospital stay in the last six months and steroids
or another immunosuppressant in the last six months. As in the
univariate analysis, antibiotics in the last six months was associated
with lower odds of C. difficile carriage. The lower odds of C. difficile
carriage with prior antibiotics in the multivariate model is
particularly driven by the low number of carriers in the group of
participants receiving antibiotics without hospital exposure in the
last six months (1/51, 2%, Table 4). However, as illustrated, the
small number of carriers means that a single change in the number
of carriers could have changed odds ratio estimates substantially.
The timing of antibiotic exposure in participants and the
antibiotics taken is given in Table 5. 44 (39%) participants were
taking antibiotics at enrolment and a further 14 (12%) had taken
antibiotics in the 2 weeks prior to enrolment. Co-amoxiclav was
the most commonly used antibiotic in 39 (35%) participants.
In a sensitivity analysis, 22 participants reporting loose or more
frequent stool, but not meeting CDI diagnosis criteria, were
excluded. Of the remaining participants 5/90 (6%) were C. difficile
carriers. The same risk factors remained in the multivariate model,
with broadly similar point estimates for the odds ratios, however
with greater uncertainty around these estimates given the smaller
numbers of participants in the analysis (Table 3).
Genetic Relationships between Carriage and
Symptomatic Isolates
The first positive isolate from the 18 participants with $1
positive sample(s) underwent whole genome sequencing. Positive
samples were obtained between 09 February 2012 and 09 June
2012 (1 in February, 2 in March, 14 in May, and 1 in June 2012,
the variation reflecting changes in recruitment and sampling
intensity). These sequences were compared with sequences
obtained from all Oxfordshire hospital and community symptom-
atic C. difficile positive samples processed by the routine OUH
microbiology laboratory between April 2011 and August 2012. All
samples were mapped to the CD630 reference genome, with a
mean of 85.1% of the reference genome called in the 18 carriage
samples, and 84.3% across the 618 comparison samples. Mean
mapped read depths were 88.9 and 84.3 respectively.
Thirteen of the asymptomatic carriage isolates sequenced (72%)
were toxigenic and from disease-causing lineages (Table 6).
Sequence types, STs, obtained from symptomatic cases and
toxigenic strains from asymptomatic carriers overlapped (Table 7).
No asymptomatic isolates from the epidemic ST1 lineage were
seen, but this is consistent with ST1 (ribotype 027/NAP1) having
largely ceased to be a cause of symptomatic disease in Oxfordshire
since 2009 [5], affecting only 9 CDI cases in our study period.
Interestingly asymptomatic carriage of an ST11 (ribotype 078), an
emerging hypervirulent strain from clade 5, was seen in one
participant, with 27 symptomatic cases over the study period.
The number of SNVs between each of the carriage samples and
the closest prior and subsequent symptomatic or asymptomatic
sample is shown in Table 8. In keeping with the significant
diversity observed in symptomatic patients [5], 9/18 (50%)
carriage isolates were .10 SNVs different from all other carriage
or disease samples. However, several isolates fell within the
diversity observed in common disease-causing sequence types. Five
participants had a sample that was #2 SNVs from at least one
other symptomatic or asymptomatic sample (i.e. consistent with
transmission based on rates of C. difficile within host diversity and
evolution [5]). Participants 2 and 3 had non-toxigenic samples
within 1 SNV of each other, but were $30 SNVs different from
any symptomatic case. Participants 7, 18, and 14 had samples
which were#1 SNV from at least one previous symptomatic toxin
A/B positive sample. Epidemiological relationships between CDI
cases and asymptomatic participants with all samples genetically
related within #2 SNVs are shown in Figure 3.
Several plausible transmission events involving asymptomatic C.
difficile carriers as recipients can be seen from the combined genetic
Table 3. Multivariate risk factors for asymptomatic carriage of C. difficile.
Participants with questionnaire data Excluding participants reporting mild diarrhoea
Risk factor Odds ratio 95% CI p value Odds ratio 95% CI p value
Current diarrhoea, but not meeting CDI criteria 10.0 (1.96, 50.9) 0.006 –
Overnight hospital stay in last 6 months 5.53 (1.06, 28.8) 0.02 5.19 (0.58, 46.0) 0.14
Antibiotics in last 6 months 0.07 (0.01, 0.45) 0.005 0.04 (0.002, 0.51) 0.01
Steroids/Immunosuppressant in last 6 months 7.19 (1.32, 39.1) 0.02 16.5 (1.25, 215) 0.03
The left hand side of the table includes all participants with questionnaire data, the right hand side excludes 22 patients with loose or more frequent stool, but not
meeting CDI diagnosis criteria (5 carriers and 17 non-carriers). No significant pairwise interactions were identified, but given the relatively small sample size the power to
detect these is low. Excluding one participant with missing hospital exposure data.
doi:10.1371/journal.pone.0078445.t003
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and epidemiological data. Participants 2 and 3 shared time on a
ward together before both were found to be asymptomatic carriers
with isolates 1 SNV different, either representing transmission
from one asymptomatic participant to another, or both having
been exposed to an un-assayed common source. Participant 18
shared time on a ward with a symptomatic patient before being
found to carry C. difficile only 1 SNV different to the symptomatic
case. The epidemiological linkage between participant 14 and the
most closely genetically related case is less strong, with only a short
overlap between the two patients 6 months prior to the
participant’s sample. Participant 79s asymptomatic carriage strain
appears to have been acquired nearly a year previously, with an
intervening symptomatic episode, while sharing time on a ward
with 3 other cases, 2 with identical sequences, and 1 a single SNV
different. Interestingly 2 of these 3 cases were EIA-negative on an
initial screen, although toxin genes were present in the sequences.
Although it can be difficult to infer the direction of transmission
with often only a single sample from asymptomatic carriers and
symptomatic cases, in this relatively small study, no clear evidence
of onward transmission from an asymptomatic case was seen
despite sequencing nearly all of the subsequent CDI cases for 3
months.
Discussion
In this study we determine the prevalence of asymptomatic C.
difficile carriage in medical inpatients in an endemic setting with
limited case-to-case transmission [5], define risk factors for
carriage, and investigate its role in onward transmission. The
Table 4. Relationship between overnight hospital stays and antibiotic exposure in the last six months amongst C. difficile carriers
and non-carriers.
Risk factor combination C. difficile carriers (% row total) Non-carriers (% row total)
Hospital + Antibiotics 5 (13%) 34 (87%)
Overnight hospital only 1 (25%) 3 (75%)
Antibiotics only 1 (2%) 50 (98%)
Neither 3 (18%) 14 (82%)
111 of the 112 participants with questionnaire data completed both questions on hospital exposure and antibiotic use.
doi:10.1371/journal.pone.0078445.t004
Table 5. Type and duration of antibiotic exposure at study
enrolment in C. difficile carriers and non-carriers.
Initial C. difficile culture
Antibiotic exposure in
last 6 months Negative Positive Total
Total participants 102 10 112
No Antibiotics 18 4 22
One or more antibiotics 84 6 90
Amoxicillin 4 4
Current at enrolment 2
#2 weeks previously 1
.2 weeks ago 1
Cephalosporin 3 3
Current at enrolment 3
Co-amoxiclav 21 3 24
Current at enrolment 13
#2 weeks previously 8 3
Flucloxacillin 4 4
Current at enrolment 4
Macrolide 2 2
Current at enrolment 1
$2 weeks ago 1
Trimethoprim 2 2
Current at enrolment 1
#2 weeks previously 1
Other 1 1
.2 weeks ago 1
Multiple* 20 2 22
Current at enrolment 18 2
.2 weeks ago 2
Unknown Agent 27 1 28
,2 weeks previously 1
$2 weeks ago 3
Unknown time
(but ,6 months)
23 1
*Of those taking multiple agents, 15 participants’ regimes included co-
amoxiclav, 7 participants a macrolide, and 3 a cephalosporin.
doi:10.1371/journal.pone.0078445.t005
Table 6. Asymptomatic carriage isolates: multilocus
sequence types, clades and toxin status.
ST Clade Toxin A/B Frequency Participant Id
2 1 +/+ 2 1, 16
3 1 +/+ 2 14, 18
6 1 +/+ 2 6, 10
7 1 2/2 1 15
11 5 +/+ 1 9
13 1 +/+ 1 17
18 1 +/+ 1 13
26 1 2/2 1 8
29 1 2/2 2 2, 3
35 1 +/+ 2 7, 11
46 1 +/+ 1 5
49 1 +/+ 1 4
125 1 2/2 1 12
Participant id follows that used in Figure 2.
doi:10.1371/journal.pone.0078445.t006
Asymptomatic C. difficile Carriage & Transmission
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e78445
T
a
b
le
7
.
C
o
m
p
ar
is
o
n
o
f
m
u
lt
ilo
cu
s
se
q
u
e
n
ce
ty
p
e
s
(S
T
s)
o
b
se
rv
e
d
in
sy
m
p
to
m
at
ic
ca
se
s
an
d
as
ym
p
to
m
at
ic
p
ar
ti
ci
p
an
ts
,
0
1
A
p
ri
l
2
0
1
1
to
3
1
A
u
g
u
st
2
0
1
2
.
S
T
A
sy
m
p
to
m
a
ti
c
p
a
rt
ic
ip
a
n
ts
(%
to
ta
l)
n
=
1
8
R
o
u
ti
n
e
ly
d
ia
g
n
o
se
d
C
D
I
(%
to
ta
l)
n
=
4
8
1
T
o
x
in
E
IA
-n
e
g
a
ti
v
e
,
cu
lt
u
re
p
o
si
ti
v
e
(%
to
ta
l)
n
=
1
3
7
A
ll
sy
m
p
to
m
a
ti
c
co
m
p
a
ri
so
n
sa
m
p
le
s
(%
to
ta
l)
n
=
6
1
8
2
2
(1
1
%
)
4
2
(9
%
)
1
4
(1
0
%
)
5
6
(9
%
)
6
2
(1
1
%
)
4
7
(1
0
%
)
6
(4
%
)
5
3
(9
%
)
8
4
3
(9
%
)
1
0
(7
%
)
5
3
(9
%
)
1
0
3
6
(7
%
)
6
(4
%
)
4
2
(7
%
)
4
4
3
0
(6
%
)
9
(7
%
)
3
9
(6
%
)
1
4
2
1
(4
%
)
8
(6
%
)
2
9
(5
%
)
7
1
(2
)
(6
%
)
1
4
(3
%
)
1
4
(1
0
%
)
2
8
(5
%
)
1
5
1
6
(3
%
)
1
2
(9
%
)
2
8
(5
%
)
1
1
1
(6
%
)
2
4
(5
%
)
3
(2
%
)
2
7
(4
%
)
5
1
8
(4
%
)
3
(2
%
)
2
1
(3
%
)
3
2
(1
1
%
)
1
5
(3
%
)
2
(1
%
)
1
7
(3
%
)
2
6
1
(2
)
(6
%
)
8
(2
%
)
7
(5
%
)
1
5
(2
%
)
5
8
1
4
(3
%
)
1
(0
.7
%
)
1
5
(2
%
)
9
1
1
(2
%
)
2
(1
%
)
1
3
(2
%
)
5
4
1
3
(3
%
)
0
(0
%
)
1
3
(2
%
)
1
6
1
1
(2
%
)
1
(0
.7
%
)
1
2
(2
%
)
3
5
2
(1
1
%
)
8
(2
%
)
4
(3
%
)
1
2
(2
%
)
4
6
1
(6
%
)
1
1
(2
%
)
0
(0
%
)
1
1
(2
%
)
3
7
8
(2
%
)
2
(1
%
)
1
0
(2
%
)
1
7
(1
%
)
2
(1
%
)
9
(1
%
)
4
9
1
(6
%
)
8
(2
%
)
1
(0
.7
%
)
9
(1
%
)
1
2
4
(0
.8
%
)
4
(3
%
)
8
(1
%
)
1
3
1
(6
%
)
6
(1
%
)
2
(1
%
)
8
(1
%
)
1
7
4
(0
.8
%
)
3
(2
%
)
7
(1
%
)
5
5
4
(0
.8
%
)
2
(1
%
)
6
(1
%
)
2
2
5
(1
%
)
0
(0
%
)
5
(0
.8
%
)
3
3
4
(0
.8
%
)
1
(0
.7
%
)
5
(0
.8
%
)
3
6
4
(0
.8
%
)
1
(0
.7
%
)
5
(0
.8
%
)
4
2
(0
.4
%
)
2
(1
%
)
4
(0
.6
%
)
4
3
3
(0
.6
%
)
1
(0
.7
%
)
4
(0
.6
%
)
4
5
3
(0
.6
%
)
1
(0
.7
%
)
4
(0
.6
%
)
4
8
1
(0
.2
%
)
3
(2
%
)
4
(0
.6
%
)
2
9
2
(2
)
(1
1
%
)
2
(0
.4
%
)
1
(0
.7
%
)
3
(0
.5
%
)
4
2
3
(0
.6
%
)
0
(0
%
)
3
(0
.5
%
)
1
8
1
(6
%
)
1
(0
.2
%
)
1
(0
.7
%
)
2
(0
.3
%
)
Asymptomatic C. difficile Carriage & Transmission
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e78445
estimated carriage point prevalence of 6% or 9% (in participants
with questionnaire data, depending on the definitions used to
define ‘‘asymptomatic’’) is consistent with previous estimates in
other populations [6,12]. The majority of asymptomatically
carried strains were toxigenic and from disease-causing genotypes.
Previous hospital exposure and steroid/immunosuppressant
medication were identified as independent risk factors for carriage
supporting recently published data from a similar study of 320
patients in North America [28]. Patient reported loose or
increased stool frequency not meeting the threshold for CDI
testing ($3 unformed stools in 24 hours) also increased the risk of
carriage; arguably these patients may have mild CDI not captured
by the commonly used threshold for testing in place in our
institution. Mandatory CDI reporting [29] may act as a
disincentive to diagnosing such cases, as may the financial
penalties imposed for excess cases in the UK [30]. Although the
benefit of treating mild CDI is uncertain [31], these patients are
still a potential source of onward transmission and therefore overly
restrictive diagnostic definitions may in fact hinder infection
control.
The finding that patient-reported antibiotic use in the last six
months was associated with decreased odds of carriage was
unexpected. Other studies have found no association with
antibiotic use [6,28] or that antibiotics were associated with
increased carriage rates [32]. There are several possible explana-
tions for our finding. Enrolment to the study was conditional on
participants not having had a recent CDI; it is therefore possible
that a proportion of patients with C. difficile carriage receiving
antibiotics were selected out, having already developed CDI.
Recall bias is a potential concern regarding antibiotic exposure
prior to the current hospital admission (hospital records were used
to determine antibiotic exposure during the current hospital
admission), particularly as our study depended on next of kin recall
in participants without capacity. More active participants with less
healthcare exposure are possibly more likely to recall antibiotic use
and have lower intrinsic risk of carriage. C. difficile strains sensitive
to antibiotics taken by participants may also have been suppressed
or removed by antibiotic use; many participants were taking
antibiotics at enrolment or had been exposed in the previous 2
weeks. Trends towards gastric acid suppression and nursing/
residential home residence increasing carriage were seen on
univariate analysis and may merit further investigation in larger
studies in future.
By using whole genome sequencing combined with ward
movement data several potential acquisitions of asymptomatic
carriage strains from symptomatic cases were observed. However,
none of the 13 asymptomatically carried toxigenic isolates were
involved in onward transmission to any CDI case diagnosed in the
region within $3 months, i.e. within current consensus on
common incubation periods [3,33]. This suggests onward trans-
mission from asymptomatic patient carriers may be infrequent
(one-tailed 97.5% exact confidence interval for proportion of
colonisations leading to a secondary case 0, 0.25). Perhaps this is
unsurprising given asymptomatic carriage is much more prevalent
than disease. If, based on this and previous studies, ,5% of those
admitted to hospital are colonised, onward transmission per case
could be infrequent but still contribute substantially to the overall
burden of disease. For example, if rates of CDI range from 1 to 10
per 1000 admissions [34], then as few as 1 in 10 to 1 in 100
asymptomatic carriers respectively would need to transmit for
transmission from asymptomatic carriage to account for 50% of all
cases. Such a pattern of transmission would be consistent with the
considerable genetic diversity seen in disease causing strains [5]. A
considerably larger study than this would be needed to estimate
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Figure 3. Epidemiological relationships between 4 asymptomatic study participants and genetically related cases. Study participants
are shown in blue, with the exception of participant 3, shown in red in the first panel. Symptomatic cases are shown as different colours, and are
distinct across different panels. Positive asymptomatic samples from study participants are shown as filled circles. Positive symptomatic samples are
shown as crosses. EIA-negative culture-positive samples are shown as diamonds. Ward stays are shown as horizontal lines with capped ends. Wards
sharing the same specialty and hospital share the same initial letter; adjacent wards forming a single unit have the same letter and number and are
followed by a lower case letter.
doi:10.1371/journal.pone.0078445.g003
Table 8. Single nucleotide variants, SNVs, between 18 asymptomatic carriage samples and most closely genetically related prior
and subsequent symptomatic/asymptomatic sample.
Participant ST Toxin A/B
SNVs to most closely
related sample
SNVs to most closely
related prior sample
SNVs to most closely related
subsequent sample
7*1 35 +/+ 0 0 21
2 29 2/2 1 1 4840
18 3 +/+ 1 1 13
3*{ 29 2/2 1 1 4817
14* 3 +/+ 1 1 278
10 6 +/+ 5 5 21
11 35 +/+ 6 10 6
6 6 +/+ 8 14 8
1 2 +/+ 10 10 14
16 2 +/+ 18 21 18
8 26 2/2 21 21 37
5 46 +/+ 24 24 48
17 13 +/+ 25 37 25
15 7 2/2 57 4558 57
12 125 2/2 61 3006 61
9 11 +/+ 461 461 1294
41 49 +/+ 944 1627 944
13*1 18 +/+ 1656 2299 1656
Participants are ordered by the number of SNVs to the most closely related sample. The participant numbering follows the same scheme used in Figure 2.
*indicates acquisition following an initially negative sample.
1indicates subsequently developed disease with the same strain,
{indicates subsequently developed disease with a different strain.
doi:10.1371/journal.pone.0078445.t008
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more precisely the proportion of asymptomatic carriers transmit-
ting onwards to a new CDI case. For example, if the expected
proportion of asymptomatic carriers transmitting onward to a case
is 5%, then 298 carriers (and all associated cases) would be needed
for the upper limit of the 95% confidence interval around the
estimated proportion of asymptomatic carriers transmitting to be
,10% with 0.95 probability [35]. Even with asymptomatic
carriage rates of ,10% this would involve a study with ,3000
participants.
This scenario has implications for further research and for
control. Research studies investigating the role of asymptomatic
carriers either need to prospectively identify and recruit consid-
erable numbers of carriers to detect a small proportion involved in
onward transmission, or studies need to rapidly follow up the
potential sources of each new case immediately after diagnosis
before the new cases have a chance to infect their contacts
themselves (as done in the study of Samore et al [20]).
If a low transmission rate from a substantial minority of
asymptomatic carriers nevertheless is an important source of
disease, then this has substantial implications for hospital infection
control, as screening and isolation or C. difficile eradication in these
carriers may interrupt transmission. However, the number needed
to isolate/treat to prevent one transmission is likely to be large,
albeit possibly still cost-effective if the prevalence of carriage and
probability of onward transmission is high enough [36] or
screening can be targeted to those most likely to carry [28]. In a
small study, vancomycin treatment did not reduce long-term
carriage, but did transiently render subjects culture-negative
during and immediately after treatment [37]. Transient suppres-
sion of carriage would probably be sufficient to reduce risk of
onward transmission throughout most patients’ hospital admission
as C. difficile was not detected until 2068 days after the end of a 10
day vancomycin course. However there is no direct evidence that
treating asymptomatic carriers or instituting more stringent
isolation of carriers leads to less transmission [38]. The closest to
this kind of evidence is a study in a Belgian leukaemia unit, where
a combination of environmental cleaning and renovation together
with treatment of asymptomatic carriers with vancomycin reduced
CDI rates markedly [39].
A major challenge in conducting this study was obtaining
samples, and especially serial samples, from patients. As designed,
opportunistically sampling patients when they open their bowels,
the study was highly acceptable to patients (and the relatives of
patients without capacity) with 230/243 (95%) of those ap-
proached agreeing to participate. However obtaining samples
therefore depended on the goodwill of ward nursing staff to assist
patients in returning samples, and on participants’ bowel habit.
Both factors contributed to relatively low rates of sample return,
with only just over half of participants recruited returning one or
more samples. An alternative approach would have been to take
rectal or perianal swabs from patients. As this is more invasive,
participation rates are likely to be lower; in a large Canadian study
using rectal swabs in some participants (and also obtaining blood
samples) participation rates were 57% [6]. However this approach
enables samples to be obtained by dedicated research staff, and
provides control over the timing of samples from consenting
patients. Although overall either approach seems to result in
similar proportions of patients being sampled at least once, if
sufficient resources are available, direct swabbing enables much
more complete serial sampling of participants. Sampling by
dedicated research staff is also likely to ensure sample return is
more sustainable.
Another important limitation in any carriage study is how
closely the limit of detection of the organism corresponds to
complete absence of the organism. In this study the culture
methods used are well supported and follow the largest study of
asymptomatic colonisation to date [6,40]. Only a single possible
false negative result was observed in a patient positive the
following day. Undetected carriage may also contribute to
transmission; although it seems plausible that C. difficile carried
in detectable quantities is more likely to be transmitted, and
therefore likely to be a more significant potential source of
infection than undetectable carriage.
Overall, this study supports data from other settings on the
prevalence of asymptomatic carriage, and provides clear evidence
for carriage of disease-causing strains. It also suggests potential
patient populations that may be at increased risk of carriage.
Whole genome sequencing provides a powerful tool for studying
potential transmission events involving asymptomatic carriers.
Preliminary findings here do not suggest these transmission events
are common at the level of individual carriers, but rather
transmission may be a relatively rare event. However as
asymptomatic carriers are a relatively large pool of patients, they
may still have an important role in onward transmission leading to
disease, which could be quantified in larger studies.
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